Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
Hsu FI, Lumry W, Riedl M, Tachdjian R. Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age. Allergy, Asthma & Clinical Immunology 2022, 18: 64. PMID: 35831891, PMCID: PMC9281160, DOI: 10.1186/s13223-022-00689-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHereditary angioedemaHealth statusAdverse fetal outcomesCohort of patientsChoice of therapyContinuity of careMedical Advisory BoardC1-INH deficiencyWomen's health statusRisk-benefit assessmentHAE attacksHAE managementFetal outcomesProphylactic therapyPatient populationTreatment optionsFemale sexDisease burdenTreatment decisionsContraceptive useUnpredictable episodesTreatment efficacyMucous membranesGynecologic specialistsPregnancyClinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor
Jones DH, Bansal P, Bernstein JA, Fatteh S, Harper J, Hsu FI, O’Connor M, Park N, Suez D. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organization Journal 2022, 15: 100621. PMID: 35145604, PMCID: PMC8804245, DOI: 10.1016/j.waojou.2021.100621.Peer-Reviewed Original ResearchManagement of HAEMost patientsHereditary angioedemaC1 esterase inhibitorAngioedema attacksHAE attacksMedian ageClinical profileSerum levelsRhC1-INHTreatment outcomesRecombinant human C1 esterase inhibitorNormal C1 esterase inhibitorEsterase inhibitorHuman C1 esterase inhibitorAcute HAE attacksHigh-dose antihistaminesUS treatment centersPatient-reported assessmentsLow serum levelsPatient-reported outcomesC1-INH deficiencyAvailability of treatmentImproved disease controlBreakthrough attacks